Archive for the ‘Food Safety News’ category

FDA strengthens requirements for surgical mesh for the transvaginal repair of pelvic organ prolapse to address safety risks

January 4, 2016

The U.S. Food and Drug Administration today issued two final orders to manufacturers and the public to strengthen the data requirements for surgical mesh to repair pelvic organ prolapse (POP) transvaginally, or through the vagina. The FDA issued one order to reclassify these medical devices from class II, which generally includes moderate-risk devices, to class […]

Thomas Produce Recalls Cucumbers because of Possible Health Risk

December 31, 2015

Thomas Produce Company of Boca Raton, FL is recalling 174 bulk-packed containers of Cucumbers. This product has the potential to be contaminated with Salmonella, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Read The Complete Story!

American Pure Whey Issues Allergy Alert on Undeclared Milk and Soy in Whey Protein Products.

December 23, 2015

American Pure Whey, New Bern, NC is recalling all lots distributed from 7/2015 to 09/2015 of the products 100% Pure Whey Protein Matrix and 100% Pure Whey Protein Isolate, because they may contain undeclared milk and soy that are present in the whey ingredient. People who have an allergy or severe sensitivity to milk and […]

FDA approves Zurampic to treat high blood uric acid levels associated with gout

December 22, 2015

The U.S. Food and Drug Administration today approved Zurampic (lesinurad) to treat high levels of uric acid in the blood (hyperuricemia) associated with gout, when used in combination with a xanthine oxidase inhibitor (XOI), a type of drug approved to reduce the production of uric acid in the body.

FDA approves new orphan drug to treat pulmonary arterial hypertension

December 22, 2015

On December 21, the U.S. Food and Drug Administration approved Uptravi (selexipag) tablets to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive, and debilitating rare lung disease that can lead to death or the need for transplantation.

FDA updates blood donor deferral policy to reflect the most current scientific evidence and continue to ensure the safety of the U.S. blood supply

December 21, 2015

Today the U.S. Food and Drug Administration issued a final guidance outlining updated donor deferral recommendations that appropriately protect the U.S. blood supply by reducing the risk of transmitting human immunodeficiency virus (HIV) infection.

FDA permits marketing of fecal continence restoration system

December 18, 2015

The U.S. Food and Drug Administration today approved the Fenix Continence Restoration System to treat fecal incontinence in patients who are not candidates for, or have previously failed, medical or other surgical options.

FDA proposes tanning bed age restrictions and other important safety measures

December 18, 2015

Today, the U.S. Food and Drug Administration announced important proposed steps ‎to protect public health by preventing the use of sunlamp products (also commonly known as indoor tanning beds) by minors and reducing the risk of using these devices for adults. The FDA is committed to protecting public health by informing consumers of the risks […]

FDA approves wearable defibrillator for children at risk for sudden cardiac arrest

December 17, 2015

The U.S. Food and Drug Administration today approved a new indication for the LifeVest wearable cardioverter defibrillator. The LifeVest is approved for certain children who are at risk for sudden cardiac arrest, but are not candidates for an implantable defibrillator due to certain medical conditions or lack of parental consent.

FDA approves wearable defibrillator for children at risk for sudden cardiac arrest

December 17, 2015

The U.S. Food and Drug Administration today approved a new indication for the LifeVest wearable cardioverter defibrillator. The LifeVest is approved for certain children who are at risk for sudden cardiac arrest, but are not candidates for an implantable defibrillator due to certain medical conditions or lack of parental consent.

FDA approves Basaglar, the first “follow-on” insulin glargine product to treat diabetes

December 16, 2015

The U.S. Food and Drug Administration today approved Basaglar (insulin glargine injection), a long-acting human insulin analog to improve glycemic control in adult and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.

FDA approves Bridion to reverse effects of neuromuscular blocking drugs used during surgery

December 15, 2015

The U.S. Food and Drug Administration today approved Bridion (sugammadex) injection to reverse the effects of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide, which are used during certain types of surgery in adults.

FDA takes action against Vermont dairy farm for illegally administering drugs to cattle

December 15, 2015

Today, the U.S. Department of Justice entered a consent decree of permanent injunction in the District of Vermont against the Correia Family Limited Partnership, doing business as Wynsum Holsteins, a dairy farm located in West Addison, Vermont, and its partners, Anthony Correia, Barbara Correia and Stephen Correia. The decree accompanies a complaint filed at the […]

FDA approves new oral therapy to treat ALK-positive lung cancer

December 11, 2015

The U.S. Food and Drug Administration today approved Alecensa (alectinib) to treat people with advanced (metastatic) ALK-positive non-small cell lung cancer (NSCLC) whose disease has worsened after, or who could not tolerate treatment with, another therapy called Xalkori (crizotinib).

FDA approves first emergency treatment for overdose of certain types of chemotherapy

December 11, 2015

The U.S. Food and Drug Administration today approved Vistogard (uridine triacetate) for the emergency treatment of adults and children who receive an overdose of the cancer treatment fluorouracil or capecitabine, or who develop certain severe or life-threatening toxicities within four days of receiving these cancer treatments.

The Sweet Leaf Tea Company Issues Voluntary Nationwide Recall of Tea in Glass Bottles

December 10, 2015

The Sweet Leaf Tea Company announced today that it is voluntarily recalling Sweet Leaf Tea in 16 ounce glass bottles out of an abundance of caution because of the possible presence of glass fragments. This was the result of glass breakage during the filling process. Read The Complete Story!

FDA allows marketing of cooling cap to reduce hair loss during chemotherapy

December 8, 2015

Today, the U.S. Food and Drug Administration cleared for marketing in the United States the first cooling cap to reduce hair loss (alopecia) in female breast cancer patients undergoing chemotherapy.

FDA approves first recombinant von Willebrand factor to treat bleeding episodes

December 8, 2015

The U.S. Food and Drug Administration today approved Vonvendi, von Willebrand factor (Recombinant), for use in adults 18 years of age and older who have von Willebrand disease (VWD). Vonvendi is the first FDA-approved recombinant von Willebrand factor, and is approved for the on-demand (as needed) treatment and control of bleeding episodes in adults diagnosed […]

FDA approves first drug to treat a rare enzyme disorder in pediatric and adult patients

December 8, 2015

Today, the U.S. Food and Drug Administration approved Kanuma (sebelipase alfa) as the first treatment for patients with a rare disease known as lysosomal acid lipase (LAL) deficiency.

Home | Copyright 2008-2024 FoodandDrugRecall.org